Cell Microarrays for High Throughput RNAi

用于高通量 RNAi 的细胞微阵列

• 批准号: 6694273
• 负责人: Jiwu Wang
• 金额: $ 9.95万
• 依托单位: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-17 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6694273
• 关键词: RNA; biotechnology; drug screening /evaluation; gene induction /repression; genetic screening; high throughput technology; microarray technology; reporter genes; technology /technique development; tissue /cell culture; transfection

DESCRIPTION (provided by applicant): The goal of this proposal is to further develop and adapt our existing DNA-based RNAi technology to a cell microarray format for high throughput gene function studies and potential drug screening efforts. The principle of arrays of living cells for "reverse transfection" has been established and applied to identifying cDNAs involved in cellular physiology changes. We will first utilize the published cell microarray method for our DNA-based RNAi system to prove the principle of microarrays of RNAi (MAR). We will then use the method to screen for genes the silencing of which will alter the expression of a reporter gene. This high throughput format of RNAi will impact the gene analysis and drug screening fields tremendously. Once we have developed this technology, we plan to take advantage of our strong collaborations and high market demand to distribute our RNAi systems throughout the biomedical field.

描述（由申请人提供）：该提案的目的是进一步开发并使我们现有的基于DNA的RNAi技术适应细胞微阵列格式，用于高通量基因功能研究和潜在的药物筛查工作。活细胞阵列的“反转染”原理已建立并应用于识别涉及细胞生理变化的cDNA。我们将首先利用已发表的基于DNA的RNAi系统的已发表的细胞微阵列方法来证明RNAi（MAR）的微阵列原理。然后，我们将使用该方法筛选基因沉默将改变报告基因的表达。 RNAi的这种高通量格式将极大地影响基因分析和药物筛查场。一旦我们开发了这项技术，我们计划利用我们的强大合作和高市场需求，以在整个生物医学领域分配我们的RNAi系统。